Marilyn Ader

Biography

Education Undergraduate: Utica College of Syracuse University, 1980 Master's: Kent State University, 1982 Doctorate: University of Southern California, 1988   Cedars-Sinai Affiliations Department of Biomedical Sciences Diabetes & Obesity Research Institute Awards & Activities Ad Hoc Member, Grant Review Panels for NIH/IPOD, NIH/Endocrinology/Metabolism/Nutrition/Reproduction, NICHD, NIMH, NIA), Department of Defense, Canadian Diabetes Assoc., BUPA Foundation, 2005-13 Standing Member, NIH Study Section (IPOD: Integrative Physiology, Obesity, and Diabetes), 2008-13 Co-Editor-in-Chief, Obesity, 2011-12 Deputy Editor-in-Chef, Obesity, 2007-11 Chair, NIH Study Section (PAR: Metabolic Effects of Psychotropic Medications), 2009 American Diabetes Association Postdoctoral Fellowship, 1988-91 First Prize, Young Investigators' Forum, American Diabetes Association, 1987

Research Interest

The overall focus of the lab of Marilyn Ader, PhD, is the pathogenesis of Type 2 diabetes, with an integrative perspective on the impact of obesity on insulin sensitivity, insulin secretion and hepatic insulin clearance. She examines the mechanisms by which multiple organ systems interact to maintain glucose homeostasis in the face of environmental and pharmacologic insults. One of her primary projects investigates mechanisms by which antipsychotic drugs induce obesity and glucose dysregulation. These studies have had major translational and public health impact, and they involve both large-animal studies and collaborative work of psychiatric patients. Ader is a leading expert in the role of insulin-independent factors, termed "glucose effectiveness," in glucose homeostasis, and has published extensively in this area in peer-reviewed papers, book chapters and reviews. Ader also examines the role of insulin clearance in determining insulin sensitivity and fasting insulin levels, and studies the impact of obesity on the contribution of liver clearance versus pancreatic β-cell insulin secretion to fasting hyperinsulinemia. Ader is also pursuing novel pancreatic islet transplant research for possible clinical treatment of Type 1 diabetes.